Owlet: High Risk, High Reward In Medical Tech And Subscription
Owlet offers the only FDA-approved wearable infant monitor and is building a subscription-based telehealth platform targeting 1 million users. The company raised its gross margin guidance to 53-55% and reaffirmed 2026 revenue of $118-$122 million, though near-term profitability remains elusive amid ongoing cash burn.
Why it matters — OWLT watchers would care because the company's pivot to recurring subscriptions and raised margin guidance signal progress, but persistent cash burn and delayed profitability remain key risks to monitor.